摘要
目的:探讨布地格福治疗慢性阻塞性肺疾病(COPD)的临床效果。方法:选择2022年6—12月盐城市滨海县人民医院呼吸与危重医学科收治的COPD患者80例作为研究对象,按照随机数字表法分为对照组和观察组,各40例。两组均采用常规治疗,对照组接受了布地奈德福莫特罗吸入粉雾剂,而观察组则采用了布地格福进行治疗。比较对照组和观察组治疗前后肺功能、血气分析指标、不良反应发生率及全因死亡率、圣乔治呼吸问卷(SGRQ)评分及COPD疾病评估测试(CAT)评分。结果:治疗后,观察组用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC高于对照组,差异有统计学意义(P<0.05);观察组动脉血氧分压、血氧饱和度水平高于对照组,动脉血二氧化碳分压水平低于对照组,差异有统计学意义(P<0.05);观察组不良反应总发生率及全因死亡率低于对照组,差异有统计学意义(P<0.05);观察组SGRQ、CAT评分均低于对照组,差异有统计学意义(P<0.05)。结论:布地格福应用在COPD患者中可改善患者肺功能及血气分析指标,提高患者活动能力及生活质量,降低不良反应发生率和患者的全因死亡率。
Objective:To explore the clinical effect of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate in treatment of chronic obstructive pulmonary disease(COPD).Methods:Eighty COPD patients treated in the Department of Respiratory and Critical Care Medicine at Binhai County People's Hospital in Yancheng City from June to December 2022 were included in this study.They were randomly divided into two equal groups,with 40 patients in each.The control group received budesonide/formoterol inhalation powder,while the observation group was treated with budesonide/formoterol.The lung function,blood gas analysis indicators,adverse reactions,all-cause mortality rate,St.George's Respiratory Questionnaire(SGRQ)scores,and COPD Assessment Test(CAT)scores were compared before and after treatment in both groups.Results:After treatment,forced vital capacity(FVC),forced expiratory volume in the first second(FEV_(1))and FEV_(1)/FVC in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).The partial pressure of oxygen and blood oxygen saturation levels in the observation group were higher than those in the control group,and the level of partial pressure of carbon dioxide in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions and all-cause mortality in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).The SGRQ and CAT scores in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).Conclusion:The application of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate in patients with COPD can improve lung function and blood gas analysis indicators,enhance patients'locomotor activity and quality of life,and reduce the incidence of adverse reactions and all-cause mortality of patients.
作者
毛静
陈国萍
Mao Jing;Chen Guoping(Department of Respiratory and Critical Care Medicine,Yancheng Binhai County People's Hospital,Yancheng 224500,Jiangsu Province,China)
出处
《中外医药研究》
2023年第34期57-59,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
关键词
布地格福
慢性阻塞性肺疾病
肺功能
全因死亡率
Budesonide,Glycopyrronium Bromide and Formoterol Fumarate
Chronic obstructive pulmonary disease
Lung function
All-cause mortality
